Protara Therapeutics, Inc. (TARA) Stock Price & Analysis
Protara Therapeutics, Inc. (TARA) — MoonshotScore 46/100 (Fair band), calculated Nov 18, 2026. Price $2.28 (-5.00%), as of the Nov 20, 2026 trading session; market cap $140M.
Educational signal · not a buy or sell recommendation · How to read this
Protara Therapeutics, Inc. · TARA · NASDAQ
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and rare diseases.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Protara Therapeutics (TARA)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, weak growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Thin; Financial Safety: Sound; Valuation: Rich; Growth Durability: Fading; Momentum: Slipping.
Free cash flow yield is the main valuation drag relative to sector peers.
- EPS beat 0 of the last 4 reports
- Altman Z 1.50 · Piotroski F 1
- ROE -57.4% · ROA -35.4% · current ratio 9.01
Holding back: a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 48 | Fair | |
| 47 | Fair | |
| 47 | Fair | |
| 46 | Fair | |
| 46 | Fair | |
| 46 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.28 | |
| Change on the day | -5.00% | |
| Market capitalisation | $140M | — |
| Shares traded on the day | 1.07M |
Price & events
Other perspectives
Council score for Protara Therapeutics (TARA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 21, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens disagrees with the Valuation pillar (Rich, 28 of 100): it reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Protara Therapeutics (TARA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Protara Therapeutics, Inc. (TARA) is listed on NASDAQ. It employs 46 people. The market values it at $140M.
What do the latest results show for Protara Therapeutics (TARA)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
What are the financial strengths and risks for Protara Therapeutics (TARA)?
Short answer
What is holding it back is a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z 1.50 · Piotroski F 1. Trailing ratios: ROE -57.4% · ROA -35.4% · current ratio 9.01.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.50 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-57.4%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Protara Therapeutics (TARA)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $22.30M · EPS -1.38 · 7 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for TARA.
Checked against the records this page reads, on the dates shown above.
How does Protara Therapeutics compare with its peers?
Short answer
Protara Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $58.80 Nov 20, 2026 | $120B | 85 5-pillar Nov 18, 2026 | |
| $270.47 Nov 20, 2026 | $651B | 83 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $133.72 Nov 20, 2026 | $330B | 69 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| Protara Therapeutics (TARA) — this page | $2.28 | $140M | 46 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $22.30M
- EPS estimate
- $-1.38
Measured against a quoted price of $2.28 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TARA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TARA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About TARA
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for TARA?
TARA carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is TARA a good stock to buy?
Stock Expert AI does not rate TARA buy, sell or hold. Protara Therapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TARA stock price today?
The last price recorded for Protara Therapeutics, Inc. (TARA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for TARA?
Protara Therapeutics, Inc. (TARA) holds a MoonshotScore in the low range. Developing intravenous choline chloride for intestinal failure associated liver disease (IFALD), addressing a critical unmet need. Not financial advice.
How frequently does TARA data refresh on this page?
TARA's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TARA's recent stock price performance?
Protara Therapeutics, Inc. (TARA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TARA overvalued or undervalued right now?
Protara Therapeutics, Inc. (TARA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of TARA?
Fractional-share availability for Protara Therapeutics, Inc. (TARA) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track TARA's earnings and financial reports?
Protara Therapeutics, Inc. (TARA) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for TARA earnings announcements.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 6 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com